Clinical testing of Conray meglumine and Amipaque in cerebral angiography.
Amipaque 280 mg I/ml and Conray meglumine 282 mg I/ml have been compared in a double-bind trial in cerebral angiography. Altogether 55 cerebral artery branches have been examined in 21 patients, who served as their own controls. The effect of the contrast injections on the intra-arterial blood pressure, pulse rate, ECG, circulatory rate and the patients' reactions were recorded under standardized conditions. The quality of the films was also evaluated. No significant difference in the cardiovascular effects of the two contrast media was found. There was a significant difference in favour of Amipaque in the discomfort of the patients--less pain and sensation of warmth. No serious side effects were observed.
D000328:Adult; D000368:Aged; D002533:Cerebral Angiography / Q000379:methods*; D004311:Double-Blind Method; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007482:Iothalamate Meglumine / Q000494:pharmacology; D008297:Male; D008793:Metrizamide / Q000494:pharmacology; D008875:Middle Aged
D008793:Metrizamide; D007482:Iothalamate Meglumine